AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30422990 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance (IMR) assessed at the time of PPCI using adenosine, median IMR 38.5 (range 9 to 202).
Number of subjects: 50
Study 30422990 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MVO) assessed by cardiovascular magnetic resonance (CMR) on day 2 following STEMI, both early MVO and late MVO measured.
Number of subjects: 50
Study 30423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for longer than 48 hours
Number of subjects: 2492
Study 30423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 2492
Study 30423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and Sequential Organ Failure Assessment Scores
Number of subjects: 2492
Study 30423165 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-recommended rivaroxaban doses
Number of subjects: 4464
Study 30423165 — intervention group
Group type: COMPARATOR
Intervention: Recommended rivaroxaban doses
Number of subjects: 4464
Study 30424962 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 53
Study 30424962 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 53
Study 30425161 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for left-sided stroke
Number of subjects: 405
Study 30425161 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for right-sided stroke
Number of subjects: 405
Study 30425640 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0
Study 30425824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Carbidopa-Levodopa (ER CD-LD)
Number of subjects: 0
Study 30425824 — intervention group
Group type: COMPARATOR
Intervention: Immediate-Release Carbidopa-Levodopa (IR CD-LD)
Number of subjects: 0
Study 30425824 — intervention group
Group type: COMPARATOR
Intervention: CD-LD + Entacapone (CLE)
Number of subjects: 0
Study 30425843 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80-120 mg/day on days 1-28 every 42 days, four courses)
Number of subjects: 1518
Study 30425843 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses)
Number of subjects: 1518
Study 30425843 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 1518
Study 30425843 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV
Number of subjects: 1518
Study 30426067 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 polyunsaturated fatty acids (1.5 g docosahexaenoic acid + eicosapentaenoic acid daily) and cocoa flavan-3-ols (500 mg n-3 FLAV daily)
Number of subjects: 259
Study 30426067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 259
Study 30426151 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 23
Study 30426396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) cohort
Number of subjects: 24245
Study 30426396 — intervention group
Group type: COMPARATOR
Intervention: Non-rheumatoid arthritis (non-RA) cohort
Number of subjects: 24245
Study 30426474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis
Number of subjects: 0
Study 30426695 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure individuals
Number of subjects: 82
Study 30427584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg b.i.d.
Number of subjects: 0
Study 30427594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Number of subjects: 0
Study 30427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered via gastroscope to the descending part of the duodenum.
Number of subjects: 13
Study 30427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 13
Study 30427906 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during morning bed bathing
Number of subjects: 60
Study 30427906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music) during morning bed bathing
Number of subjects: 60
Study 30428708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation intervention (details not specified)
Number of subjects: 0
Study 30428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, neuropsychological, neuroimaging, and biological markers assessment
Number of subjects: 214
Study 30428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments every 6 months for 24 months
Number of subjects: 214
Study 30428896 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based assessment
Number of subjects: 19
Study 30428896 — intervention group
Group type: COMPARATOR
Intervention: CMS20s reference system
Number of subjects: 19
Study 30428931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell infusion
Number of subjects: 404
Study 30429013 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint integrating neurological symptoms, cerebrospinal fluid parameters, and CNS imaging
Number of subjects: 49
Study 30429013 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR activating mutations
Number of subjects: 49
Study 30429013 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint for objective response evaluation of LM
Number of subjects: 49
Study 30429013 — intervention group
Group type: EXPERIMENTAL
Intervention: Status of EGFR activating mutations
Number of subjects: 49
Study 30429013 — intervention group
Group type: EXPERIMENTAL
Intervention: T790M occurrence in CNS lesions
Number of subjects: 49
Study 30429112 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity habit strength
Number of subjects: 790
Study 30429112 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 790
Study 30429112 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity treatment with social support
Number of subjects: 790
Study 30429114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management app
Number of subjects: 0
Study 30429371 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated MMP-9 in COPD subjects
Number of subjects: 1193
Study 30429768 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct-Current Stimulation (HD-tDCS)
Number of subjects: 0
Study 30429768 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Transcranial Direct-Current Stimulation (tDCS)
Number of subjects: 0
Study 30429772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical recordings from the motor cortex during attempted grasps of four objects
Number of subjects: 1
Study 30429772 — intervention group
Group type: EXPERIMENTAL
Intervention: Active grasping of a virtual object with appropriate force
Number of subjects: 1
Study 30430021 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LDG)
Number of subjects: 0
Study 30430021 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 0
Study 30430326 — intervention group
Group type: EXPERIMENTAL
Intervention: HighQ (best image quality, n=177)
Number of subjects: 605
Study 30430326 — intervention group
Group type: COMPARATOR
Intervention: LowQ (lower image quality, n=428)
Number of subjects: 605
Study 30431292 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about ovarian cancer risk
Number of subjects: 1100
Study 30431292 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive screening events (FPSE)
Number of subjects: 1100
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative BuChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Postoperative day 1 BuChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Postoperative day 2 BuChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative AChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Postoperative day 1 AChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: COMPARATOR
Intervention: Postoperative day 2 AChE activity
Number of subjects: 650
Study 30431498 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of BuChE activity by 100 U/L
Number of subjects: 650
Study 30431498 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of AChE activity by 1 U/g of hemoglobin
Number of subjects: 650
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pneumonia
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission for pneumonia
Number of subjects: 5094
Study 30431500 — intervention group
Group type: COMPARATOR
Intervention: No pneumonia
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative SpO2 values while breathing room air
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative colloid administration
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative blood transfusion
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site (open upper abdominal surgery)
Number of subjects: 5094
Study 30431500 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance
Number of subjects: 5094
Study 30439678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 or 20 mg)
Number of subjects: 0
Study 30439678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30439678 — intervention group
Group type: COMPARATOR
Intervention: Active reference drug (paroxetine [20 mg] or escitalopram [10 or 20 mg])
Number of subjects: 0
Study 30439678 — intervention group
Group type: EXPERIMENTAL
Intervention: UPSA
Number of subjects: 0
Study 30439678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of all studies
Number of subjects: 0
Study 30442120 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intervention combining hypnosis and self-care
Number of subjects: 88
Study 30442120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 30442205 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 14
Study 30442245 — intervention group
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy (NIRS) monitoring
Number of subjects: 152
Study 30442245 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring
Number of subjects: 152
Study 30442257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anaesthesia
Number of subjects: 0
Study 30442257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BRS
Number of subjects: 0
Study 30442257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative BRS
Number of subjects: 0
Study 30442257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-emetics
Number of subjects: 184
Study 30442259 — intervention group
Group type: COMPARATOR
Intervention: Preoperative values
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: BARF and VAS nausea scores correlation
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: BARF and pain score correlation
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: BARF and VAS clinically relevant difference
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: BARF intra-class coefficient
Number of subjects: 184
Study 30442259 — intervention group
Group type: EXPERIMENTAL
Intervention: BARF scale performance
Number of subjects: 184
Study 30442260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated abdominal compression with a pressure of 25 mm Hg
Number of subjects: 39
Study 30442260 — intervention group
Group type: COMPARATOR
Intervention: Volume expansion (VE) of 10 ml/kg
Number of subjects: 39
Study 30442264 — intervention group
Group type: EXPERIMENTAL
Intervention: ASOS Surgical Risk Calculator
Number of subjects: 8799
Study 30442497 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 31321
Study 30442502 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2857916 (3.40 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 2)
Number of subjects: 73
Study 30442502 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2857916 (0.03-4.60 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 1)
Number of subjects: 73
Study 30442503 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m²
Number of subjects: 198
Study 30442638 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 (Teaching + Tailoring)
Number of subjects: 200
Study 30442638 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 (Teaching + Tailoring + Technology)
Number of subjects: 200
Study 30442638 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 4 (Teaching + Tailoring + Technology + Touch)
Number of subjects: 200
Study 30442638 — intervention group
Group type: COMPARATOR
Intervention: Level 1 (Teaching; Control)
Number of subjects: 200
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Disease Activity (VLDA)
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-perceived remission
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Disease Activity (MDA)
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-perceived LDA
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-perceived remission/LDA
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPSA-defined remission/LDA
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDA/MDA
Number of subjects: 410
Study 30442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-perceived remission/LDA using a single question
Number of subjects: 410
Study 30442743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-STEACS pathway
Number of subjects: 1920
Study 30442743 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 1 hour pathway
Number of subjects: 1920
Study 30442743 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 3 hour pathway
Number of subjects: 1920
Study 30442743 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 1920
Study 30443431 — intervention group
Group type: EXPERIMENTAL
Intervention: DMD mutation location downstream of exon 51
Number of subjects: 204
Study 30443431 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid use
Number of subjects: 204
Study 30443549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied sensors for assessing the quality of 18F-FDG injections
Number of subjects: 0
Study 30443549 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Positron Emission Tomography (PET) images
Number of subjects: 0
Study 30443801 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPET
Number of subjects: 41
Study 30443801 — intervention group
Group type: COMPARATOR
Intervention: Patlak analysis
Number of subjects: 41
Study 30443801 — intervention group
Group type: COMPARATOR
Intervention: Hunter method
Number of subjects: 41
Study 30443801 — intervention group
Group type: COMPARATOR
Intervention: Barbolosi-Bl method
Number of subjects: 41
Study 30443801 — intervention group
Group type: COMPARATOR
Intervention: Barbolosi-Im method
Number of subjects: 41
Study 30443916 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 2 years post-discharge for ACS
Number of subjects: 10568
Study 30443916 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for MACCE
Number of subjects: 10568
Study 30443916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MACCE risk during 2 years of follow-up
Number of subjects: 10568
Study 30444200 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific 153z CART treatment
Number of subjects: 1
Study 30444200 — intervention group
Group type: EXPERIMENTAL
Intervention: CD28/IL-15Rα co-signaling (153z) CAR
Number of subjects: 1
Study 30444258 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 0
Study 30444283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal CPAP (8-10 cm H2O) for 4 weeks
Number of subjects: 55
Study 30444283 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 4 weeks
Number of subjects: 55
Study 30444283 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment
Number of subjects: 55
Study 30444530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation group (n=35)
Number of subjects: 70
Study 30444530 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 70
Study 30444686 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of chemotherapy
Number of subjects: 49
Study 30444686 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of chemotherapy
Number of subjects: 49
Study 30444686 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of chemotherapy
Number of subjects: 49
Study 30444686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive chemotherapy for infants younger than 2 months with hepatomegaly
Number of subjects: 49
Study 30444686 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 49
Study 30445678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 42
Study 30445678 — intervention group
Group type: COMPARATOR
Intervention: Oral P2Y12-inhibitors
Number of subjects: 42
Study 30446007 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9150 at 2 mg/kg
Number of subjects: 30
Study 30446007 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9150 at 3 mg/kg
Number of subjects: 30
Study 30446007 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9150 (both doses)
Number of subjects: 30
Study 30446206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulation of amino acids (AAs)
Number of subjects: 516
Study 30446206 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (control group)
Number of subjects: 516
Study 30446354 — intervention group
Group type: EXPERIMENTAL
Intervention: HFmrEF
Number of subjects: 1065
Study 30446354 — intervention group
Group type: COMPARATOR
Intervention: HFpEF
Number of subjects: 1065
Study 30446499 — intervention group
Group type: EXPERIMENTAL
Intervention: TUBB1 mutations
Number of subjects: 0
Study 30446575 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to the 2015 ACR guideline
Number of subjects: 200
Study 30446741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anti-thymocyte globulin (ATG) 5 mg/kg and low-dose posttransplant cyclophosphamide (PTCy) 50 mg/kg
Number of subjects: 32
Study 30446785 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 1000 mg qd
Number of subjects: 35
Study 30446785 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 400 mg bid
Number of subjects: 35
Study 30446785 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 1200 mg qd
Number of subjects: 35
Study 30446785 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 1400 mg qd
Number of subjects: 35
Study 30446785 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (both dosing schedules)
Number of subjects: 35
Study 30447530 — intervention group
Group type: EXPERIMENTAL
Intervention: Privigen® (IgPro10, CSL Behring)
Number of subjects: 181
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic N-acetylaspartate (NAA) concentration
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination at 6 hours
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination at discharge
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal amplitude integrated EEG at 6 hours
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MRI - cortical injury
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MRI - basal ganglia or thalamic injury
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MRI - abnormal signal in the posterior limb of internal capsule (PLIC)
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional anisotropy of PLIC
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS metabolite peak-area ratios of NAA-creatine (<1.29)
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS metabolite peak-area ratios of NAA-choline
Number of subjects: 223
Study 30447969 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS metabolite peak-area ratios of lactate-NAA (>0.22)
Number of subjects: 223
Study 30448116 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with low-gradient aortic stenosis (EUS patients)
Number of subjects: 0
Study 30448278 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB patients during pregnancy
Number of subjects: 25
Study 30448278 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB patients during extended OGTT
Number of subjects: 25
Study 30448278 — intervention group
Group type: COMPARATOR
Intervention: RYGB group post-delivery
Number of subjects: 25
Study 30448343 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with FLOT in combination with surgical resection of the primary tumour and metastases
Number of subjects: 0